Vonoprazan‐ vs proton‐pump inhibitor‐based first‐line 7‐day triple therapy for clarithromycin‐susceptibleHelicobacter pylori: A multicenter, prospective, randomized trial

Helicobacter ◽  
2017 ◽  
Vol 23 (2) ◽  
pp. e12456 ◽  
Author(s):  
Soichiro Sue ◽  
Marina Ogushi ◽  
Isao Arima ◽  
Hirofumi Kuwashima ◽  
Satoshi Nakao ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Randomized Trial ◽  
Triple Therapy ◽  
Proton Pump ◽  
Prospective Randomized Trial ◽  
First Line

scholarly journals Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin

2010 ◽  
Vol 47 (1) ◽  
pp. 53-58 ◽  
Author(s):  
Makoto Sasaki ◽  
Naotaka Ogasawara ◽  
Keiko Utsumi ◽  
Naohiko Kawamura ◽  
Tskeshi Kamiya ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Proton Pump Inhibitor ◽  
Triple Therapy ◽  
Proton Pump ◽  
Eradication Rate ◽  
First Line

Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy forHelicobacter pylorieradication

2014 ◽  
Vol 23 (5) ◽  
pp. 443-455 ◽  
Author(s):  
Chen-Li Ye ◽  
Guo-Ping Liao ◽  
Shuai He ◽  
Yan-Na Pan ◽  
Ying-Bo Kang ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Triple Therapy ◽  
Proton Pump ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Qiu-Ju Lyu ◽  
Qiang-Hong Pu ◽  
Xian-Fei Zhong ◽  
Jin Zhang
Keyword(s):  
Helicobacter Pylori ◽  
Proton Pump Inhibitor ◽  
Triple Therapy ◽  
Proton Pump ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
First Line ◽  
H Pylori

Aims. To compare the efficacy and safety of vonoprazan-based versus proton pump inhibitor (PPI)-based triple therapy in the eradication of Helicobacter pylori. Methods. We performed a systematic search in PubMed, Embase, and the Cochrane Library databases for relevant randomized controlled trials up to March 2019. Studies were included if they compared the efficacy and safety of H. pylori eradication of vonoprazan-based and PPI-based triple therapy. Results. Three studies with 897 patients were evaluated in this meta-analysis. The H. pylori eradication rate of vonoprazan-based triple therapy was higher than that of PPI-based triple therapy as first-line regimens (intention-to-treat analysis: pooled eradication rates, 91.4% vs 74.8%; odds ratio [OR], 3.68; 95% confidence interval (CI): [1.87–7.26]; P<0.05). The incidence of adverse events in vonoprazan-based triple therapy was lower than that in PPI-based triple therapy (pooled incidence, 32.7% vs 40.5%; OR, 0.71; 95%CI: [0.53–0.95]; P<0.05). Conclusions. Efficacy of vonoprazan-based triple therapy is superior to that of PPI-based triple therapy for first-line H. pylori eradication. Additionally, vonoprazan-based triple therapy is better tolerated than PPI-based triple therapy.

Sign in / Sign up

Export Citation Format

Share Document